Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | FDPS | P14324 | 1/20 | 0.35 |
| ▸ | ARG1 | P05089 | 1/20 | 0.32 |
| ▸ | ARG2 | P78540 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3971250 | 0.88 | FDPS (0.39) | ALDH1A1MEN1CYP1A2THRBKMT2A | |
| SCHEMBL5394315 | 0.86 | MEN1 (0.37) | ALDH1A1MEN1CYP1A2THRBKMT2A | |
| SCHEMBL3809015 | 0.72 | ALDH1A1 (0.40) | ALDH1A1MEN1THRBKMT2AFDPS | |
| SCHEMBL6729367 | 0.70 | ALDH1A1 (0.59) | ALDH1A1MEN1THRBKMT2AFDPS | |
| SCHEMBL5391004 | 0.70 | — | — | |
| SCHEMBL28399096 | 0.70 | ALDH1A1 (0.43) | ALDH1A1MEN1THRBKMT2AFDPS | |
| SCHEMBL5403337 | 0.70 | SMN1; SMN2 (0.50) | ALDH1A1CYP1A2ARG1ARG2LMNA | |
| SCHEMBL10937553 | 0.69 | MEN1 (0.33) | ALDH1A1MEN1CYP1A2THRBKMT2A | |
| Hydrochloric Acid SCHEMBL28019265 | 0.68 | MEN1 (0.34) | ALDH1A1MEN1CYP1A2THRBKMT2A | |
| Hydrochloric Acid SCHEMBL11348309 | 0.68 | ALDH1A1 (0.34) | ALDH1A1FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7498436-B2 | Substituted hydroxyethylamines | PHARMACIA & UPJOHN COMPANY LLC (US) | 2009-03-03 | — | — | US | disclosed |
| US-7214715-B2 | Compounds to treat Alzheimer's disease | PHARMACIA & UPJOHN (US) | 2007-05-08 | — | — | US | disclosed |
| US-20060106256-A1 | Substituted hydroxyethylamines | PHARMACIA & UPJOHN COMPANY | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106256-A1 | Substituted hydroxyethylamines | HNMT, PNMT, BCHE | ALDH1A1 589/4885MEN1 815/4885CYP1A2 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.